iPhone app iPad app Android phone app Android tablet app More

Medical Device Industry Wants To Speed Up FDA Approval Amid Safety Concerns

Medical Devices

First Posted: 02/15/2012 1:37 pm Updated: 02/15/2012 1:38 pm

Is it more important to speed up the approval of medical devices for patients in pain or to make sure that they're safe?

That question is being debated today at a Congressional hearing amid fierce lobbying that pits the medical device industry against some consumer groups.

At issue is a new agreement to double the user fees paid by device makers to the Food and Drug Administration; the fees help fund the agency's review of their products. In exchange, the industry wants to speed up the approval process, claiming that crucial devices to help treat suffering patients are being needlessly delayed in FDA bureaucracy.

But groups like Public Citizen want the FDA to reject that request and are demanding more stringent oversight for medical devices, citing statistics that show the average number of high-risk recalls in 2011 is more than double that of recent years.

The $350 billion industry that makes products like heart stents and artificial hips spent $33 million on lobbying last year with an army of 225 lobbyists, including 107 who used to work in government, pressing the issue with lawmakers.

On the consumer side, Lana Keeton has been stalking the halls of Congress to push for tougher regulation of the industry. After she suffered numerous complications from surgery in 2001 to implant a synthetic mesh bladder sling, she founded her own patient advocacy organization, Truth in Medicine.

"We're becoming a nation of cripples with stuff that's supposed to save our lives," Keaton told the Austin American-Statesman.

PIPELINE SAFETY REGULATORS ACCUSED OF BEING 'ASLEEP AT THE SWITCH'

Federal pipeline safety regulators were "asleep at the switch" and "shirked their duty," leading up to the deadly 2010 Pacific Gas and Electric pipe blast in San Bruno, according to a lawsuit filed by San Francisco Tuesday against the Pipeline and Hazardous Materials and Safety Administration [PHMSA].

City Attorney Dennis Herrera holds the agency responsible for not enforcing pipeline safety rules and not putting pressure on state regulators who failed to carry out their duties.

The bulk of pipeline oversight is conducted by state inspectors, many of whom have been furloughed for weeks at a time, according to a new Congressional Research Service report obtained by the Federation for American Scientists.

Budget problems at state pipeline safety agencies are a matter of "great concern" to the PHMSA and it is possible that some states may drop their safety programs or lose federal certification due to poor performance, according to the CRS. The report's authors also recommended that the agency take a more direct role in the operation of pipelines through corrective orders or shutdown orders rather than increasing monetary penalties, since such fines hardly impact major energy companies.

A PHMSA spokesman emailed the following statement to the Watchdog:

PHMSA is committed to its core responsibility to protect people and the environment. That's why we devoted hundreds of hours of staff support and technical expertise to the NTSB and the California Public Utilities Commission to understand the San Bruno tragedy. We will keep working with state and local officials and communities, including San Francisco, who share a common responsibility to improve pipeline safety. However, we cannot comment on pending legal matters.

TODAY'S MUST-READ

"Now that the suspicion of insider trading is increasing, regulators, who have had little to say about imposing rules on the $346 billion of unregistered credit-default swaps, may be forced to increase control over Wall Street's hottest and darkest market." (Bloomberg News)

QUICK HITS

  • Goldman Sachs and Morgan Stanley finally filed their comment letters on the Volcker rule and they recite many of the same arguments commonly heard on Wall Street though MS ups the ante with its claim that the rule hurts its ability to help Montana wind farms and bankrupt airlines.
  • The Commodity Futures Trading Commission is planning to shift enforcement staff to meet Dodd-Frank rules and to toughen its oversight of the futures market, in the wake of its failure to adequately supervise the CME Group, the Chicago Board of Trade and ICE Futures last year.
  • Whistleblowing accountant Kristy Ferara appears to have filed a claim against pharma giant Novartis over possible tax evasion though details remain murky.
  • That "new car smell" might not be so pleasant after you're done reading a new report from HealthyStuff.org about the toxic chemicals inherent in interior auto parts such as seating, dashboards and vehicle trim. Pollutants such as benzene, toluene and xylene were found in levels exceeding air quality standards.

FOLLOW HUFFPOST BUSINESS

Is it more important to speed up the approval of medical devices for patients in pain or to make sure that they're safe? That question is being debated today at a Congressional hearing amid fierce ...
Is it more important to speed up the approval of medical devices for patients in pain or to make sure that they're safe? That question is being debated today at a Congressional hearing amid fierce ...
 
 
  • Comments
  • 28
  • Pending Comments
  • 0
  • View FAQ
Post Comment Preview Comment
To reply to a Comment: Click "Reply" at the bottom of the comment; after being approved your comment will appear directly underneath the comment you replied to.
View All
Favorites
Recency  | 
Popularity
photo
LunaPark
Don't believe it until it's officially denied
10:40 PM on 02/15/2012
The FDA is out of control, corrupt, and staffed with industry insiders who are intent on keeping competition away from big pharma by granting monopoly power to corporations. They need to go. The FDA is a part and parcel why there is a shortage of critical cancer drugs, and why drug costs are so sky high.
photo
HUFFPOST SUPER USER
chris hatala
05:56 PM on 02/15/2012
Congress should be the guinea pigs for these devises.
photo
rudyg43
2014 Mid-term is a coming!
05:41 PM on 02/15/2012
The first guinea pigs to test these new units should be those wanting to speed up the testing and approval for mass use. Throwing more money at FDA bureaucracy will grease and speed up the process, but that would be a waste of money. Recall's of stent's placed into patient's is an unacceptable process and procedure as it could and does lead to further complications of patient care. Any and all material being put into place for patient health and well-being is tantamount to be checked over and over to insure the highest quality of devices utilized or implanted. Short-cuts are an unacceptable Modus Operandi..Short-cuts if taken should be done on those wanting a faster testing and turn-around. Human life is more precious than profits.
06:28 PM on 02/15/2012
"Recall's of stent's placed into patient's is an unacceptab­le process and procedure"

No process or product in the world has a defective rate of 0%.
HUFFPOST SUPER USER
onionboy
Blessed are the Cheese Makers
03:42 PM on 02/15/2012
Device are already being approved TOO fast, far faster and easier than drugs or biologics. What they really want is a return to the 'good old days' when devices were hardly FDA regulated at all and they didn't have to deal with the same hurdles as drug and biologic makers. They're upset that they can carry their money home in a wheelbarrow instead of the pick-up they used to need.
06:29 PM on 02/15/2012
"Device are already being approved TOO fast,"

Proof? Oh that is right you don't have any. Except for the voice in your head that keeps whispering "Device are already being approved TOO fast".
HUFFPOST SUPER USER
onionboy
Blessed are the Cheese Makers
07:05 PM on 02/15/2012
I've been in the medical research field for 20+ years.

510k approval are 90-120 days. PMAs are 6-12 months. But NDAs and BLAs are 2-3x longer.

Let's talk about the time lag time prior to submission, the actual clinical trials. For NDAs and BLAs; after years of Phase 1-2 trials, they'll need to do a massive Phase 3 pivotal trial at a cost of 10s-100s of millions and all of this will take 4-10 years from patent. Devices...meh...single trials of a couple hundred subjects will do...no long term data needed.

Look at the regulations, even by sheer volume, and it's clear how much easier things are for device manufacturers than for drug and biologic manufacturers.

Don't mind the recalls of ICDs, hip replacements, spinal discs, etc. Nothing to see there. Yes, devices are being approved too fast already, and even more so in Europe, though they do their regulatory process a little differently.
nothingchanges
too soon old, too late smart
03:16 PM on 02/15/2012
Remember when there was some concern a while back about having too many x-rays?

That the risks were not appreciated by the general public?

How many, I wonder are aware that a CT scan of your brain exposes you to the equivalent of 100 chest x-rays?

Or that a single CT scan of the abdomen exposes you to the equivalent of 400 chest x-rays.

CT's and many new technologies are wonderful, and they provide absolutely exquisite imaging, but the potential for abuse is there.

How many CT's are ordered because a simple x-ray might not sound so good in court (defensive medicine, instead of real medicine). or worse. How many CT's are ordered, to pay for that new CT machine we just had to have to keep up with everyone else?

ALL the pluses and minuses of any medical procedure need to be considered.

IMPO.........In America, they rarely are, all TOO often the decisions are based mostly on money.
photo
HUFFPOST SUPER USER
madisonhack
I prefer not to......
05:29 PM on 02/15/2012
MRI's are more expensive, but also have higher resolution and have no radiation. Ask for one if you're being referred for a CT.
This user has chosen to opt out of the Badges program
photo
HST
Conservatism = selfishness
09:08 PM on 02/15/2012
And have the Gadolinium dye fry your kidneys? No thanks.

Gadolinium Side Effects Could Result In Kidney Failure Lawsuits
http://www.yourlawyer.com/topics/overview/gadolinium

Most Nephrogenic Systemic Fibrosis Cases Linked to 3 MRI Contrast Agents
http://www.aboutlawsuits.com/nsf-cases-linked-to-3-contrast-agents-11062/
HUFFPOST SUPER USER
Elsa Weber
02:32 PM on 02/15/2012
Before the 1920s, going to the doctor was a gamble with less than a 50% chance that the doctor might be able to help you. it was common for patients to end up in worse condition or dead. With the help of big pharma, medical device industry and the health insurance companies it is being pushed back to that place again.
groucho42
Radical Moderate
02:32 PM on 02/15/2012
Considering how many drugs and devices the FDA approves only to have the products pulled off the market when the risks are clear, I'd think speeding up approvals is the opposite of what needs to happen. What the companies are requesting is the usual "The 1% is all that matters" attempt to suck money out of the 99% to enrich a few regardless of the dangers to the many. And they whine about "class warfare"?
06:30 PM on 02/15/2012
"Considerin­g how many drugs and devices the FDA approves only to have the products pulled off the market when the risks"

I take it you have statistics on the percentage of approved drugs that get pulled off the market? 10%? 1%? 0.1%?

Oh wait, you don't have any evidence. You are just making stuff up to fit your religious beliefs of always more gubment.
02:16 PM on 02/15/2012
How come with the high costs-the devices are not safe?